# Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

> **NCT07697833** · PHASE4 · NOT_YET_RECRUITING · sponsor: **National Institute of Cardiovascular Diseases, Pakistan** · enrollment: 500 (estimated)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** Vericiguat tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07697833
- **Lead sponsor:** National Institute of Cardiovascular Diseases, Pakistan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-07-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697833, "Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*